Harrow announced an initiative to expand access and affordability for its ophthalmic pharmaceutical products. This effort includes a program of targeted price reductions for several Harrow products and a strategic partnership with GoodRx, providing patients with discounts on select Harrow products. 
 
A core component of Harrow’s Access and Affordability Program is reducing the prices of several widely used eye-care products, the company said in a press release. Harrow’s program began this week with price reductions for VIGAMOX and MAXIDEX, with the analysis of additional products underway. By lowering these costs, Harrow said it aims to improve patient access to high-quality eye-care products.
 
In addition, Harrow has partnered with GoodRx to provide a cash-pay alternative for the purchase of select Harrow products, including FLAREX, ILEVRO, MAXIDEX, TOBRADEX ST, VEVYE, VIGAMOX and ZERVIATE. This alternative to traditional insurance offers patients discounted pricing through the GoodRx platform, the company said in the press release. By leveraging GoodRx’s reach, Harrow said it is meeting the needs of those who may not have adequate insurance coverage for the eye-care medications they need.
 
“Our company was founded on a mission to help patients manage and preserve their sight by providing access to innovative and affordable medicines, and these initiatives are a significant step in advancing that mission,” said Mark L. Baum, chairman and chief executive officer of Harrow. “Patients often tell us that insurance co-payments can make their medications cost-prohibitive. By reducing prices and providing new access points, we’re creating a win-win: helping patients access critical sight-saving treatments while simultaneously delivering improved value to Harrow’s shareholders.”

Patients can search for participating pharmacies and access discounts directly through the GoodRx website or mobile app.